Centenara Labs, formerly Rejuveron, rebrands to focus on anti-ageing research
FiercePharma - 23-Sep-2024Their lead treatment, EA-2353, shows promising safety results for retinitis pigmentosa
Join the club for FREE to access the whole archive and other member benefits.
Senior editor of FierceBiotech
Business, science and healthcare journalist who has worked as an editor for Pharmafocus (UK), as a group editor for Pharmaceutical Marketing Europe, as well as a features and news writer for the BMJ and the Pharmaceutical Journal.
He has an especial interest in market access, drug pricing and the ethics of the life sciences industry and has been heavily involved in ensuring that the need for greater clinical study transparency remains on the agenda for the industry.
Visit website: https://www.fiercebiotech.com/author/ben-adams
See also
Web resource providing the latest biotech news, articles, and resources related to biotech company news
Details last updated 17-Jul-2020
Their lead treatment, EA-2353, shows promising safety results for retinitis pigmentosa
Supports ageing research and advancing early-stage projects to phase 2 trials over the next decade
rGDF11 in clinic targets multiple age related disease therapies
Novel autophagy-based approaches target muscular dystrophy and other challenging diseases
Biological clocks are a moving target so they'll need other researchers to corroborate their analysis